What's in Simcere Pharmaceutical Co., Ltd's pipeline?

Simcere Pharmaceutical Co., Ltd has 7 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Simcere Pharmaceutical Co., Ltd's portfolio?

Top competitors by shared drug class: 3D Medicines (Sichuan) Co., Ltd., AstraZeneca, GC Biopharma Corp, Green Cross Corporation, New Mexico Cancer Research Alliance.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/simcere-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Simcere Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Simcere Pharmaceutical Co., Ltd pipeline: 1 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Gemcitabine-Cisplatin chemotherapy	Gemcitabine-Cisplatin chemotherapy	marketed	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking)	Oncology
Edaravone Dexborneol Sequential Therapy	Edaravone Dexborneol Sequential Therapy	phase 3	Neuroprotective agent combination		Neurology
SIM0718 Injection	SIM0718 Injection	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)	Virology / Immunology
SIM0916	SIM0916	phase 3

Therapeutic area mix

Neurology · 1
Oncology · 1
Virology / Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
AstraZeneca · 1 shared drug class
GC Biopharma Corp · 1 shared drug class
Green Cross Corporation · 1 shared drug class
New Mexico Cancer Research Alliance · 1 shared drug class
Saol Therapeutics Inc · 1 shared drug class
Staidson (Beijing) Biopharmaceuticals Co., Ltd · 1 shared drug class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Simcere Pharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). Simcere Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/simcere-pharmaceutical-co-ltd. Accessed 2026-05-15.